Statement Of Cash Flows [Abstract]

Biotest AG - Filing #6464577

Concept	2024-01-01 to 2024-12-31	As at 2024-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	As at 2022-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Interest paid, classified as operating activities	203,000,000 EUR	—	242,000,000 EUR	—	—
Cash flows from (used in) operating activities	609,000,000 EUR	—	27,000,000 EUR	—	—
Cash flows from (used in) investing activities [abstract]
Cash flows from losing control of subsidiaries or other businesses, classified as investing activities	– EUR	—	350,000,000 EUR	—	—
Proceeds from sales of property, plant and equipment, classified as investing activities	2,000,000 EUR	—	10,000,000 EUR	—	—
Interest received, classified as investing activities	11,000,000 EUR	—	11,000,000 EUR	—	—
Cash flows from (used in) investing activities	257,000,000 EUR	—	13,000,000 EUR	—	—
Cash flows from (used in) financing activities [abstract]
Proceeds from borrowings, classified as financing activities	1,974,000,000 EUR	—	101,000,000 EUR	—	—
Repayments of borrowings, classified as financing activities	2,251,000,000 EUR	—	120,000,000 EUR	—	—
Payments of lease liabilities, classified as financing activities	51,000,000 EUR	—	70,000,000 EUR	—	—
Dividends paid, classified as financing activities	16,000,000 EUR	—	– EUR	—	—
Other inflows (outflows) of cash, classified as financing activities	10,000,000 EUR	—	21,000,000 EUR	—	—
Cash flows from (used in) financing activities	354,000,000 EUR	—	68,000,000 EUR	—	—
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes	2,000,000 EUR	—	82,000,000 EUR	—	—
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents	1,000,000 EUR	—	1,000,000 EUR	—	—
Cash and cash equivalents	—	1,078,000,000 EUR	—	1,081,000,000 EUR	1,166,000,000 EUR